MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its first quarter 2025 financial results release for May 15, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update.
Investors can access the conference call via dial-in numbers 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 9822477. A live webcast and replay will be available through the company's investor relations website.
MiNK Therapeutics (NASDAQ: INKT), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie con cellule iNKT invariant, allogeniche e pronte all'uso, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per il 15 maggio 2025, prima dell'apertura dei mercati. La societ脿 terr脿 una conference call e una webcast alle 8:30 a.m. ET per discutere i risultati e fornire un aggiornamento aziendale.
Gli investitori potranno partecipare alla conference call chiamando i numeri 646-307-1963 (New York) o 800-715-9871 (USA e Canada) utilizzando il codice di accesso Conference ID 9822477. La diretta webcast e la registrazione saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda.
MiNK Therapeutics (NASDAQ: INKT), una compa帽铆a biofarmac茅utica en etapa cl铆nica enfocada en el desarrollo de terapias con c茅lulas iNKT invariantes, alog茅nicas y listas para usar, ha programado la publicaci贸n de sus resultados financieros del primer trimestre de 2025 para el 15 de mayo de 2025, antes de la apertura del mercado. La compa帽铆a realizar谩 una conferencia telef贸nica y una transmisi贸n web a las 8:30 a.m. ET para discutir los resultados y proporcionar una actualizaci贸n corporativa.
Los inversores podr谩n acceder a la conferencia telef贸nica marcando los n煤meros 646-307-1963 (Nueva York) o 800-715-9871 (EE.UU. y Canad谩) usando el ID de conferencia 9822477. La transmisi贸n en vivo y la repetici贸n estar谩n disponibles en el sitio web de relaciones con inversionistas de la compa帽铆a.
MiNK Therapeutics (NASDAQ: INKT)電� 霃欖 鞚挫嫕鞖�, 歃夓嫓 靷毄 臧�電ロ暅 攵堧硛 鞛愳棸 靷错暣 T(iNKT) 靹疙彫 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 鞝滌暯 須岇偓搿�, 2025雲� 1攵勱赴 鞛 瓴瓣臣 氚滍憸毳� 2025雲� 5鞗� 15鞚� 鞁滌灔 臧滌灔 鞝勳溂搿� 鞓堨爼頄堨姷雼堧嫟. 須岇偓電� 霃欕秬 響滌鞁� 鞓れ爠 8鞁� 30攵�鞐� 瓴瓣臣毳� 雲检潣頃橁碃 旮办梾 鞐呺嵃鞚错姼毳� 鞝滉车頃橁赴 鞙勴暣 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
韴瀽鞛愲摛鞚� 646-307-1963 (雺挫殨) 霕愲姅 800-715-9871 (氙戈淡 氚� 旌愲倶雼�)搿� 鞝勴檾頃橃棳 旎嵓霟办姢 ID 9822477鞚� 靷毄頃� 旎嵓霟办姢 旖滌棎 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 霛检澊敫� 鞗轨簮鞀ろ姼 氚� 雲鬼檾氤胳潃 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞝滉车霅╇媹雼�.
MiNK Therapeutics (NASDAQ: INKT), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies cellulaires iNKT invariantes allog茅niques pr锚tes 脿 l'emploi, a programm茅 la publication de ses r茅sultats financiers du premier trimestre 2025 pour le 15 mai 2025, avant l'ouverture des march茅s. La soci茅t茅 organisera une conf茅rence t茅l茅phonique et un webcast 脿 8h30 ET pour discuter des r茅sultats et fournir une mise 脿 jour d'entreprise.
Les investisseurs peuvent acc茅der 脿 la conf茅rence t茅l茅phonique en composant les num茅ros 646-307-1963 (New York) ou 800-715-9871 (脡tats-Unis et Canada) en utilisant l'ID de conf茅rence 9822477. Un webcast en direct et une rediffusion seront disponibles sur le site des relations investisseurs de la soci茅t茅.
MiNK Therapeutics (NASDAQ: INKT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung allogener, sofort verf眉gbarer, invarianten nat眉rlichen Killer-T-Zelltherapien (iNKT) spezialisiert hat, hat die Ver枚ffentlichung der Finanzergebnisse f眉r das erste Quartal 2025 f眉r den 15. Mai 2025 vor B枚rsen枚ffnung geplant. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und Webcast veranstalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren k枚nnen die Telefonkonferenz 眉ber die Einwahlnummern 646-307-1963 (New York) oder 800-715-9871 (USA & Kanada) mit der Konferenz-ID 9822477 erreichen. Ein Live-Webcast und eine Aufzeichnung werden 眉ber die Investor-Relations-Website des Unternehmens verf眉gbar sein.
- None.
- None.
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 9822477
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company鈥檚 website at and via .
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
听听
Media Contact
781-674-4428
听听聽
FAQ
When will MiNK Therapeutics (INKT) release Q1 2025 earnings?
How can I join MiNK Therapeutics (INKT) Q1 2025 earnings call?
What type of therapies does MiNK Therapeutics (INKT) develop?
Where can I find the webcast replay of INKT's Q1 2025 earnings call?
